Δ
To discuss or comment on this announcement please visit our Investor Hub.
Race Oncology (“Race”) is pleased to announce that it has been issued a new patent…
United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE…
Race Oncology has announced it has secured a new patent on its cancer drug, Zantrene®,…